Overview A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL) Status: Recruiting Trial end date: 2021-09-01 Target enrollment: Participant gender: Summary This is a study to evaluate the safety and efficacy of TQ-B3525 tablets in patients with relapsed / refractory mantle cell lymphoma (MCL). Phase: Phase 2 Details Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.